SCHEMBL2939210

SCHEMBL2939210

COCCCn1cnc2cc(C(=O)OC)ccc21

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 1/20 0.54
HPGD P15428 3/20 0.51
MAPT P10636 3/20 0.50
POLB P06746 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
TP53 P04637 1/20 0.47
KDM4E B2RXH2 1/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
MAPK1 P28482 2/20 0.45
HSD17B10 Q99714 1/20 0.45
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
CYP1A2 P05177 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
HTT P42858 1/20 0.44
HDAC1 Q13547 2/20 0.43
LMNA P02545 1/20 0.43
EHMT2 Q96KQ7 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2935051 0.90 MTNR1A (0.48) FGFR1HPGDMAPTPOLBSMN1; SMN2
SCHEMBL2937848 0.89 HCAR3 (0.55) FGFR1HPGDMAPTSMN1; SMN2TP53
SCHEMBL1539106 0.88 HPGD (0.60) FGFR1HPGDMAPTPOLBSMN1; SMN2
SCHEMBL1307034 0.86 FGFR1 (0.57) FGFR1HPGDMAPTPOLBSMN1; SMN2
SCHEMBL1307255 0.85 FGFR1 (0.56) FGFR1HPGDMAPTPOLBSMN1; SMN2
SCHEMBL13668130 0.84 FGFR1 (0.51) FGFR1HPGDMAPTPOLBSMN1; SMN2
SCHEMBL13668129 0.83 FGFR1 (0.50) FGFR1HPGDMAPTPOLBSMN1; SMN2
SCHEMBL11679816 0.83 FGFR1 (0.60) FGFR1HPGDMAPTPOLBSMN1; SMN2
SCHEMBL29737945 0.82 KMT2A (0.55) FGFR1HPGDMAPTPOLBSMN1; SMN2
SCHEMBL28754371 0.82 KMT2A (0.55) FGFR1HPGDMAPTPOLBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1836163-B1 PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN NOVARTIS AG (CH) 2010-09-22 EP disclosed
US-20100087427-A1 PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN BREITENSTEIN WERNER 2010-04-08 US disclosed
EP-1836163-A2 PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN Novartis AG (CH) 2007-09-26 EP disclosed
WO-2006066896-A2 PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN NOVARTIS AG (CH) 2006-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087427-A1 PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN REN, ACE, PEPD FGFR1 2284/4885HPGD 137/4885MAPT 1893/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.